Proliferation is an important part of cancer development and progression. This is manifest by
altered expression and/or activity of cell cycle related proteins. Constitutive activation of …

Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

The Philadelphia chromosome, a chromosomal abnormality that encodes BCR–ABL1, is the
defining lesion of chronic myelogenous leukaemia (CML) and a subset of acute …

Vascular safety is an emerging issue in patients with chronic myeloid leukemia (CML)
treated with tyrosine kinase inhibitors (TKIs). Whereas imatinib exhibits a well-documented …

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the
haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t …

Accumulating lines of experimental evidence have revealed that hypoxia‐inducible factors,
HIF‐1α and HIF‐2α, are key regulators of the adaptation of cancer‐and metastasis‐initiating …

ABL1 tyrosine-kinase inhibitors (TKI) are front-line therapy for chronic myelogenous
leukaemia and are among the best-known examples of targeted cancer therapeutics …

The BCR-ABL1 oncoprotein transforms pluripotent HSCs and initiates chronic myeloid
leukemia (CML). Patients with early phase (also known as chronic phase [CP]) disease …

MicroRNAs and heterogeneous ribonucleoproteins (hnRNPs) are posttranscriptional gene
regulators that bind mRNA in a sequence-specific manner. Here, we report that loss of miR …

DNA damage responses (DDR) encompass DNA repair and signal transduction pathways
that effect cell cycle checkpoint arrest and/or apoptosis. How DDR pathways respond to low …